BOEHRINGER, LILLY START TRAJENTA MARLINAT CLINICAL TRIAL (ENG)

     (The following press release from Boehringer Ingelheim was received by 
e-mail. It was not confirmed by the sender.) 
Dear Sir/Madam, 
Enclosed you will find our latest press release 
For Non-U.S. and Non-U.K. Media 
Boehringer Ingelheim and Lilly initiate MARLINA(tm) clinical trial to
evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and
albuminuria 
which can be accessed at: 
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/19_ma
rch_2013_linagliptin.html 
All interested users with a web-enabled mobile phone, iPhone, Blackberry, PDA
or other mobile device now have fast access to selected, up-to-the-minute
information about Boehringer Ingelheim.
Just follow: http://mobile.boehringer-ingelheim.com/ 
Mit freundlichen Grüßen / Kind regards, 
Arnd Prilipp 
Boehringer Ingelheim GmbH
Launch + establ. Products CVM
Tel.: +49 (6132) 77-2091
Fax: +49 (6132) 77-6601
mailto:press@boehringer-ingelheim.com 
Visit us...
 <http://www.boehringer-ingelheim.com/>  <<Picture (Device Independent
Bitmap)>>  <http://www.facebook.com/boehringeringelheim>  <<Picture (Device
Independent Bitmap)>>  <http://www.twitter.com/boehringer>  <<Picture (Device
Independent Bitmap)>>  <http://www.youtube.com/boehringeringelheim>  
<<Picture (Device Independent Bitmap)>>
<http://www.flickr.com/photos/125yearsmorehealth/>  <<Picture (Device
Independent Bitmap)>> 
Boehringer Ingelheim GmbH, Unternehmensleitung: Prof. Dr. Dr. Andreas Barner
(Sprecher), Hubertus von Baumbach, Prof. Dr. Wolfram Carius, Engelbert Tjeenk
Willink; Vorsitzender des Aufsichtsrates: Christian Boehringer, Sitz:
Ingelheim am Rhein; Registergericht Mainz: HR B 21005  
Diese E-Mail ist vertraulich zu behandeln. Sie kann besonderem rechtlichen
Schutz unterliegen. Wenn Sie nicht der richtige Adressat sind, senden Sie
bitte diese E-Mail an den Absender zurück, löschen die eingegangene E-Mail
und geben den Inhalt der E-Mail nicht weiter. Jegliche unbefugte Bearbeitung,
Nutzung, Vervielfältigung oder Verbreitung ist verboten. / This e-mail is
confidential and may also be legally privileged. If you are not the intended
recipient please reply to sender, delete the e-mail and do not disclose its
contents to any person. Any unauthorized review, use, disclosure, copying or
distribution is strictly prohibited.
 
 
Press spacebar to pause and continue. Press esc to stop.